MADRSMontgomery-Asberg Depression Rating Scale
MADRSMedicare Automated Data Retrieval System
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The contacted patients had a mean baseline HAM-D score of 20.37 (range 17-24) and a mean baseline MADRS score of 27.12 (range 21-32).
(31,32) These two 8-week studies showed that quetiapine 300 mg/d or 600 mg/d significantly improved symptoms of depression according to a decrease in MADRS scores compared with placebo.
The primary outcome was depressive symptomology with the dietary group demonstrating significantly greater improvement in MADRS scores between baseline and 12 weeks than the social support control.
The QIDS-SR total score was significantly correlated with the MADRS total score (r=0.698, p<0.001).
At the end of 8 weeks, the mean (standard deviation [SD]) changes in MADRS scores from baseline were: light monotherapy 13.4 (7.5), fluoxetine monotherapy 8.8 (9.9), combination therapy 16.9 (9.2), and placebo 6.5 (9.6).
The mean change in MADRS score from the start of the study through 8 weeks was 16.9 for combination therapy, 13.4 for fight therapy, 8.8
Independent interviewers, who were blind to participants' SCID-I psychiatric diagnosis, applied the MADRS. The duration of the interviews ranged from 60 to 90 minutes for the SCID-I and ranged from 10 to 40 minutes for the MADRS.
There was also no group significant difference in the 2 depression scores (MADRS and BDI) and physical performance (handgrip strength and sit-and-reach distance) at baseline (Table 1).
In addition, the MADRS increased for each subject after endotoxin administration, whereas no significant change was noted with the placebo.
Compared with placebo, NAC treatment resulted in significant improvements on the Montgomery Asberg Depression Rating Scale (MADRS; p = 0.002), the Bipolar Depression Rating Scale (p = 0.012), and several other ratings of clinical status, quality of life, and functioning.
There will be a clinically and statistically significant post-treatment reduction in the magnitude of clinically depressed adults' scores on the Beck Depression Inventory (BDI), Subjective Units of Distress Scale (SUDS), and the Montgomery Asberg Depression Rating Scale (MADRS), as well as a significant post-treatment increase in the magnitude of participants' scores on the Lifeworks Joy Inventory (LJI).
Medicare identification numbers were solicited from the sample members, and utilization and expenditure data were derived from the Health Care Financing Administration's (HCFA) Medicare Automated Data Retrieval System (MADRS) Part A - Part B skeleton file.